EQUINOX NEPREMICNINE d.d. Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-	0.87	0.71	0.54
Depreciation & Amortization	-	3.76	3.41	3.43
Change in Accounts Receivable	-	-0.35	0.01	15.01
Change in Other Net Operating Assets	-	0.4	3.47	-0.3
Other Operating Activities	-	1.07	0.64	-3.64
Operating Cash Flow	-	5.7	8.29	14.87
Operating Cash Flow Growth	-	-31.19%	-44.24%	-
Acquisition of Real Estate Assets	-	-2.25	-5.75	-0.23
Sale of Real Estate Assets	-	0.14	-	-
Net Sale / Acq. of Real Estate Assets	-	-2.11	-5.75	-0.23
Investment in Marketable & Equity Securities	-	-3.08	1.04	-8.17
Other Investing Activities	-	1.18	0.3	0.08
Investing Cash Flow	-	-4.01	-4.42	-8.33
Long-Term Debt Issued	-	3.88	9.98	-
Long-Term Debt Repaid	-	-9.63	-9.38	-
Total Debt Repaid	-	-9.63	-9.38	-0.38
Net Debt Issued (Repaid)	-	-5.75	0.6	-0.38
Common Dividends Paid	-	-2.57	-	-
Other Financing Activities	-	-0.53	-0.36	-0.16
Miscellaneous Cash Flow Adjustments	-	0	-	4.05
Net Cash Flow	-	-7.15	4.11	10.05
Cash Interest Paid	-	0.53	0.36	0.16
Levered Free Cash Flow	-	3.44	3.58	-
Unlevered Free Cash Flow	-	3.84	4.11	-
Change in Net Working Capital	-	0.16	0.01	-

Source: S&P Capital IQ. Real Estate template. Financial Sources.